Search company, investor...
CerTest Biotec company logo

CerTest Biotec

Founded Year


Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+20 points in the past 30 days

About CerTest Biotec

CerTest Biotec is a biotechnology company dedicated to the development and manufacture of in vitro diagnostic products with human applications. It provides products for clinical diagnosis with the highest standards of quality, sensitivity, specificity, and reproducibility, allowing the identification of pathogens in the early stages of infection.

Headquarters Location

Polígono Industrial Río Gállego II

Zaragoza, 50840,


(+34) 976 520 354

Missing: CerTest Biotec's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CerTest Biotec's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing CerTest Biotec

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CerTest Biotec is included in 1 Expert Collection, including Health Monitoring & Diagnostics.


Health Monitoring & Diagnostics

702 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

CerTest Biotec Patents

CerTest Biotec has filed 1 patent.

The 3 most popular patent topics include:

  • Antibodies
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date


Related Topics




Monoclonal antibodies, Immune system, Immunology, Clusters of differentiation, Antibodies


Application Date


Grant Date



Related Topics

Monoclonal antibodies, Immune system, Immunology, Clusters of differentiation, Antibodies



Latest CerTest Biotec News

Fecal Pancreatic Elastase Testing Market Analysis by Size, Share, Growth, Trends up to 2032

Oct 10, 2022

Fecal Pancreatic Elastase Testing Market Analysis by Size... Search jobs Fecal Pancreatic Elastase Testing Market Analysis by Size, Share, Growth, Trends up to 2032 From 2022 to 2032, the faecal pancreatic elastase testing market size is expected to increase by 7.7% CAGR, surpassing US$ 14.4 Mn in 2022. The most recent analysis indicates that in 2021, faecal pancreatic elastase ELISA kits held a sizable market share of more than 99.0% worldwide. Fecal pancreatic elastase testing demand is increasing globally due to rising prevalence of exocrine pancreatic insufficiency (EPI) globally. Furthermore, growing incidence of chronic pancreatitis is expected to drive the growth in the global fecal pancreatic elastase testing market over the forecast period. A list of Key Players Covered in the Fecal Pancreatic Elastase Testing Market Are: Laboratory Corporation of America® Holdings DiaSorin Vitassay Healthcare, S.L.U. Download Sample Copy @ Chronic pancreatitis is a leading cause for EPI. According to the National Pancreases Foundation, every year around 10-12 people out of 100,000 are affected by chronic pancreatitis in industrialized countries. With prevalence of chronic pancreatitis, the number of EPI cases is also increasing. Hence, to test or diagnose EPI in chronic pancreatitis, the demand for fecal pancreatic elastase testing industry is surging globally. The demand in the market is also predicted to rise with rising number of diagnostic labs offering FE-1 testing. Traditionally, exocrine pancreatic insufficiency was measured using the fecal fat test. The hospital laboratories and diagnostic laboratories have started using the determination of pancreatic elastase from the stool sample. In the last few years, there has been an increase in the number of diagnostic laboratories offering this test. Some of the diagnostic laboratories offering this test include Mayo Clinic Laboratories, Dr Lal PathLabs, and others. Key Takeaways from Market Study By product, fecal pancreatic elastase ELISA kits are expected to hold over 99.0% market value share by the end of 2032 and are expected to display growth at 7.7% CAGR over the forecast period. By indication, chronic pancreatitis will register 7.1% CAGR with the market share value of 34.7% over the forecast period. By end-user, hospitals held the highest segment share in terms of the market share value of 37.2% in 2021. Europe is considered the leading region with a value share of 43.4% in 2021, owing to the presence of advanced testing laboratories in the region with advanced techniques and equipment. Request for Customization @ “With increasing prevalence of chronic pancreatitis, the fecal pancreatic elastase testing market is expected to witness an advancement over the forecast period,” says an analyst of Future Market Insights. Market Competition Key players are adopting strategies such as mergers and acquisition of companies to expand their global presence. Market players such as DiaSorin, BioCheck Inc., and CerTest Biotec S.L., are enhancing their presence to gain competitive edge. In August 2021, BioCheck Inc acquired the international segment of DRG Diagnostics, which improved its diagnostic segment. In July 2021, Luminex Corporation was acquired by DiaSorin. This acquisition by DiaSorin gives access to strengthen its existing offering while expanding the Group presence in the U.S. In August 2019, CerTest Biotec S.L. has expanded its solutions for the diagnosis of infectious diseases in Japan and Germany. Want more insights? Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2032. The global fecal pancreatic elastase testing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on fecal pancreatic elastase testing market segment based on product– (fecal pancreatic elastase ELISA kits and rapid fecal pancreatic elastase kits), by indication (chronic pancreatitis, type 1 diabetes, cystic fibrosis, and others) by the end-user (hospitals, diagnostics laboratories, and speciality clinics) across seven major regions. Top Related Reports Healthcare Market Insights

CerTest Biotec Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CerTest Biotec Rank

CerTest Biotec Frequently Asked Questions (FAQ)

  • When was CerTest Biotec founded?

    CerTest Biotec was founded in 2002.

  • Where is CerTest Biotec's headquarters?

    CerTest Biotec's headquarters is located at Polígono Industrial Río Gállego II, Zaragoza.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.